Remarkable migration propensity of dental pulp stem cells towards neurodegenerative milieu: An in vitro analysis

Senthilkumar, Sivapriya; Venugopal, Chaitra; Parveen, Shagufta; Shobha, KL; Kiranmai, S.; Kutty, Bindu M.; Dhanushkodi, Anandh

doi:10.1016/j.neuro.2020.08.006

Cited by 15 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local delivery of GMSC-derived exosomes could markedly improve sciatic nerve regeneration and functional recovery (Mao et al, 2019). Additionally, DPSCs have superior migration potential toward the neurodegenerative milieu compared with BMSCs (Senthilkumar et al, 2020). Collectively, these studies indicate that DMSC-derived exosomes and/or DMSC-conditioned medium can be effective in neuroregeneration, through regulating anti-inflammatory, neurogenic, anti-apoptotic, angiogenic, and osteogenic mediators.…”

Section: Repair or Regeneration Of Neural Tissuementioning

confidence: 84%

Dental-Derived Mesenchymal Stem Cells: State of the Art

Ouchi

Cao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) could be identified in mammalian teeth. Currently, dental-derived MSCs (DMSCs) has become a collective term for all the MSCs isolated from dental pulp, periodontal ligament, dental follicle, apical papilla, and even gingiva. These DMSCs possess similar multipotent potential as bone marrow-derived MSCs, including differentiation into cells that have the characteristics of odontoblasts, cementoblasts, osteoblasts, chondrocytes, myocytes, epithelial cells, neural cells, hepatocytes, and adipocytes. Besides, DMSCs also have powerful immunomodulatory functions, which enable them to orchestrate the surrounding immune microenvironment. These properties enable DMSCs to have a promising approach in injury repair, tissue regeneration, and treatment of various diseases. This review outlines the most recent advances in DMSCs’ functions and applications and enlightens how these advances are paving the path for DMSC-based therapies.

show abstract

Section: Repair or Regeneration Of Neural Tissuementioning

confidence: 84%

Dental-Derived Mesenchymal Stem Cells: State of the Art

Ouchi

Cao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…In treating various refractory clinical diseases, the directional migration of MSCs in peripheral blood is also essential for its immune regulation and tissue repair function in the damaged tissue area. 48 Our results showed that the MACS group has the highest migration capability of all groups (Figure 2B ).…”

Section: Resultsmentioning

confidence: 65%

“…Using in vitro adhesion experiments, we found that CD106 + hUC‐MSCs in the MACS group presented the strongest adhesion ability, and especially significantly better than that of the CON + group, while CD106 − hUC‐MSCs in the CON − group presented the weakest adhesion ability (Figure 2A). In treating various refractory clinical diseases, the directional migration of MSCs in peripheral blood is also essential for its immune regulation and tissue repair function in the damaged tissue area 48 . Our results showed that the MACS group has the highest migration capability of all groups (Figure 2B).…”

Section: Resultsmentioning

confidence: 75%

An optimized method for obtaining clinical‐grade specific cell subpopulations from human umbilical cord‐derived mesenchymal stem cells

et al. 2022

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are heterogeneous populations with broad application prospects in cell therapy, and using specific subpopulations of MSCs can enhance their particular capability under certain conditions and achieve better therapeutic effects. However, no studies have reported how to obtain high-quality specific MSC subpopulations in vitro culture. Here, for the first time, we established a general operation process for obtaining high-quality clinical-grade cell subpopulations from human umbilical cord MSCs (hUC-MSCs) based on particular markers. We used the MSC-CD106 + subpopulations, whose biological function has been well documented, as an example to explore and optimize the crucial links of primary preparation, pre-treatment, antibody incubation, flow sorting, quality and function test. After comprehensively evaluating the quality and function of the acquired MSC-CD106 + subpopulations, including in vitro cell viability, apoptosis, proliferation, marker stability, adhesion ability, migration ability, tubule formation ability, immunomodulatory function and in vivo wound healing ability and proangiogenic activity, we defined an important pre-treatment scheme which might effectively improve the therapeutic efficiency of MSC-CD106 + subpopulations in two critical clinical application scenarios-direct injection after cell sorting and post-culture injection into bodies. Based on the above, we tried to establish a general five-step operation procedure for acquiring high-quality clinical-grade MSC subpopulations based on specific markers, which cannot only improve their enrichment efficiency and the reliability of preclinical studies, but also provide valuable methodological guidance for the rapid clinical transformation of specific MSC subpopulations.Yali Jia and Ailing Wang contributed equally and must be considered as co-first authors.

show abstract

“…MSCs, in fact, modify their cellular signaling in reaction to primed culture conditions, and thereby administration of the primed MSCs potentiates their function, survival, and therapeutic efficacy. Multiple priming strategies have been investigated, in particular priming with inflammatory cytokines or mediators, growth factors, and hypoxia [ 182 ]. The drawback of this plan is the restricted consensus in cell manufacturing protocols, bringing about the difficulty in attaining quality assurance for clinical-grade MSCs.…”

Section: Conclusion and Future Directionmentioning

confidence: 99%

Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects

et al. 2022

View full text Add to dashboard Cite

Recently, mesenchymal stromal cell (MSC)-based therapy has become an appreciated therapeutic approach in the context of neurodegenerative disease therapy. Accordingly, a myriad of studies in animal models and also some clinical trials have evinced the safety, feasibility, and efficacy of MSC transplantation in neurodegenerative conditions, most importantly in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD). The MSC-mediated desired effect is mainly a result of secretion of immunomodulatory factors in association with release of various neurotrophic factors (NTFs), such as glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF). Thanks to the secretion of protein-degrading molecules, MSC therapy mainly brings about the degradation of pathogenic protein aggregates, which is a typical appearance of chronic neurodegenerative disease. Such molecules, in turn, diminish neuroinflammation and simultaneously enable neuroprotection, thereby alleviating disease pathological symptoms and leading to cognitive and functional recovery. Also, MSC differentiation into neural-like cells in vivo has partially been evidenced. Herein, we focus on the therapeutic merits of MSCs and also their derivative exosome as an innovative cell-free approach in AD, HD, PD, and ALS conditions. Also, we give a brief glimpse into novel approaches to potentiate MSC-induced therapeutic merits in such disorders, most importantly, administration of preconditioned MSCs.

show abstract

Remarkable migration propensity of dental pulp stem cells towards neurodegenerative milieu: An in vitro analysis

Cited by 15 publications

References 49 publications

Dental-Derived Mesenchymal Stem Cells: State of the Art

Dental-Derived Mesenchymal Stem Cells: State of the Art

An optimized method for obtaining clinical‐grade specific cell subpopulations from human umbilical cord‐derived mesenchymal stem cells

Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects

Contact Info

Product

Resources

About